Review Article

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer

Table 2

In vitro studies with bortezomib.

CarcinomaCell linesEffectsReferences

Multiple myelomaMM.1S, MM.1R, Dox40, MR20, LR5, RPMI8226, IM-9, U266, ARH-77, Hs SultanIkBa degradation, inhibited IL-6-triggered activation of p42/44 MAPK as well as TNF-a induced activation of NF-κB,Hideshima et al., 2001 [7]

Mantle cell lymphomaMino, DB (sp53), Molt-4, L-428NF-κB activation, bcl-xL and bfl/A1 inhibition, and bcl-2 cleavagePham et al., 2003 [8]

NSCLCH460, H322, H358, H157, A549Cell cycle arrest at G2-M; Bcl-2 phosphorylation and cleavage; p53 stabilization; induction of p21Cip; increase in cyclins A and B; activation of CDKs; mitochondrial cytochrome c release; activation of caspase pathway; apoptosis; NF-κB DownregulationLing et al., 2002 [9],
2003 [10], and 2003 [11]; Denlinger et al., 2004 [12]

ProstatePC-3 (p53 null)Cell cycle arrest at G2-M; increase in p21Cip; inhibition of CDK4 activity; PARP cleavage; apoptosisAdams et al., 1999 [13]
LNCaP-Pro5Activation of caspase-3; apoptosisWilliams et al., 2003 [14]

PancreaticMIA-PaCa-2Enhanced cytotoxic effects of gemcitabine;
reduced NF-κB activation; reduced Bcl-2 expression without affecting Bax or Bak; PARP cleavage; apoptosis
Bold et al., 2001 [15]
BxPC3Cell cycle arrest in G0–G1; increase in p21Cip; caspase-3 activation; apoptosisShah et al., 2001 [16]

SCCHNUM-SCC-9, UM-SCC-11BCell cycle arrest in G2-M and S phases; increase in p21Cip; apoptosis; (PARP cleavage shown in murine SCCHN lines); NF-κB DownregulationSunwoo et al., 2001 [17]

OvarianSKOV 3Induction of p21Cip; inactivation of Bcl-xL; Downregulation of XIAP; PARP cleavage; activation of caspase pathway; apoptosisFrankel et al., 2000 [18]

BreastMCF-7Cytotoxicity (molecular markers not determined)Teicher et al., 1999 [19]

ColorectalLOVO, KM12L4, WiDRInhibits chemotherapy-induced NF-κB activation; enhances chemotherapy-induced apoptosis; stabilizes p53, p21Cip; p27KipCusack Jr. et al., 2001 [20]

Adapted from Ludwig et al. [21].